Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent weight problems assembly this weekend as they prepare for the subsequent sea change in how sufferers obtain their medicine.

Novo Nordisk on Sunday introduced that prescriptions of the Wegovy pill have topped 3 million because it entered the U.S. market about 5 months in the past. The Danish drugmaker’s CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was in a position to speed up prescriptions even as Lilly launched its personal GLP-1 pill in April.

“If that is not acceleration, then I do not know what’s,” Doustdar advised CNBC this weekend at the American Diabetes Affiliation’s Scientific Periods. 

In the meantime, Lilly CEO Dave Ricks advised CNBC that prescriptions of its pill Foundayo are “markedly greater” than the 20,000 that Lilly reported about six weeks in the past round its first-quarter earnings launch, with out giving a selected quantity. He stated the quantity builds week over week and that Lilly is happy with the progress. 

The competitors for the weight reduction pill market is barely the newest for the longtime rivals. Indicators of that pressure have been evident all through the business occasion this weekend. Vehicles drove round promoting Novo’s Wegovy pill, whereas footage of Lilly’s Foundayo pill coated a few of the flooring of the conference heart in New Orleans.

And the two firms will quickly make their case for their each day capsules and their weekly photographs to seniors. Beginning in July, thousands and thousands of individuals with Medicare will probably be in a position to entry GLP-1 medicine for weight reduction for $50 a month. Till now, Medicare beneficiaries have had to pay out of pocket for the weight problems medicine, costing them probably a whole bunch of {dollars} a month. Each firms say they’re targeted on elevating consciousness of the program, although they have completely different pitches.

Doustdar thinks the program may very well be a possibility to regain a few of the floor Novo’s Wegovy shot has misplaced to Lilly’s Zepbound. The drugmaker plans to promote Wegovy’s different well being advantages on its label, he stated, like the undeniable fact that it could possibly lower the threat of cardiovascular issues like coronary heart assaults and strokes. He stated Novo ought to win with seniors “if widespread sense is to prevail, and I put myself of their footwear.”

“With the Wegovy excessive dose, why would you not take a product that has the identical efficacy, share clever, than my competitor?” he stated. “On high of it, you get kidney, liver, coronary heart, stroke safety, as an instance freed from cost. I’d take it if I used to be 10 years older.”

Lilly’s pitch to seniors is comfort. The corporate’s pill Foundayo could be taken at any time of day with meals, water and different medicines, whereas Novo’s pill wants to be taken on an empty abdomen with little water and requires fasting for half-hour afterward.  

“The primary factor is, it is easy,” Ricks stated. “That is one thing that may simply go in your each day routine. Most seniors are on many different medicines, and they’ve acquired their pill case, and they use that day-after-day, and this may simply match proper into that with none further thought.”

Ricks stated Lilly is working intently with the authorities to prepare, and he is assured that Humana, which can course of prescription requests, will do a great job. He thinks the program will probably be fashionable with seniors and that long run, the initiative might assist show that weight problems care ought to be “common well being care.” 

“We’ve to show that on this pilot and show price effectiveness and then type of reset what we anticipate from our medical insurance, which is weight problems care ought to be well being care,” Ricks stated. 

Lilly and Novo are making an attempt to improve insurance coverage coverage of GLP-1 medicine for weight problems. Not less than one evaluation discovered the medicine to be price efficient, however employers have balked at paying for them as a result of so many individuals may very well be eligible for the remedies and many sufferers cease them after reaching a weight reduction purpose. Medical health insurance firm Cigna final week stated it might cease protecting the medicines for its personal staff.

At Lilly, lower than 20% of the firm’s beneficiaries are utilizing the medicine for weight reduction, and individuals are staying on them, Ricks stated. Lilly is conducting an inside examine to measure its well being prices and outcomes like hospitalization fee, development to diabetes and cardiovascular occasions. Lilly plans to publish these outcomes later this 12 months, he stated.

Whereas they prepare for Medicare coverage, each firms are making an attempt to introduce extra medicine to deal with weight problems. At the convention this weekend, Lilly introduced Section 3 knowledge for retatrutide, an experimental triple agonist that helped individuals lose a median of 28% of their physique weight when they stayed on the drug. Practically half of individuals misplaced greater than 30% of their physique weight, an quantity that is comparable to bariatric surgical procedure. The drug additionally helped enhance associated circumstances like knee osteoarthritis and sleep apnea.

Initially, Ricks expects retatrutide to primarily be used to deal with individuals with greater physique mass indexes, or BMI. He additionally sees promise for the second-lowest power of the drug. It helped individuals lose a median of 19% of their physique weight with fewer uncomfortable side effects than the greater strengths.

One query was whether or not Lilly would make retatrutide out there on its direct-to-consumer gross sales platform LillyDirect as soon as it is permitted by the Meals and Drug Administration as a result of it is so highly effective. Lilly “completely” plans to make the drug out there there, Ricks stated.

For Novo, the subsequent drug on the horizon is known as CagriSema. It combines the major ingredient of Wegovy with one other molecule referred to as cagrilintide, which mimics one other hormone referred to as amylin. The drug’s efficacy has underwhelmed buyers because it has confirmed weight reduction that’s comparable to Lilly’s Zepbound and lower than Lilly’s retatrutide. Doustdar thinks the drug’s edge in effectiveness over Wegovy, even when just a few share factors, is significant, and stated he is dedicated to launching CagriSema. Novo expects an approval resolution from the U.S. Meals and Drug Administration on the drug in the fourth quarter of this 12 months.

“If I’ve to overlook about CagriSema, quite a lot of different merchandise have to be forgotten about as nicely,” Doustdar stated. “I do not suppose it ought to work that approach.”

Doustdar took over as chief govt virtually one 12 months in the past after a significant shakeup that led to the departure of the firm’s former chief and 1000’s of staff being laid off. He is tasked with reinvigorating gross sales of Wegovy, the firm’s pipeline and its inventory worth. Ultimately, he stated Novo will probably be extra diversified inside the space of cardiometabolic well being — like diabetes and weight problems — and a few of the “adjacencies.”

In the meantime, Doustdar stated the early success of the Wegovy pill has helped Novo regain some momentum.

“The pill was an important instance of individuals getting assured that we will do that, that at Novo Nordisk, higher days are forward of them and not simply behind,” he stated. “So we even have to actually guarantee that we flip these constructive moments that proper now we’re in right into a long run development, so we acquire the belief day-to-day and enhance that each internally as nicely as, in fact, externally, and I’ll work exhausting to guarantee that this continues.”